title: [Trigger point therapy for myofascial pain in cancer patients (first report)-analysis results of special use-results surveillance by Neovitacain® injection-].
abstract: Special use-results surveillance was conducted to examine the safety and efficacy of trigger point (TP) therapy by Neovitacain ®injection (NV) in the daily clinical treatment of myofascial pain in cancer patients. The case report forms of 175 patients were collected from 43 nationwide facilities and all of them were analyzed in terms of safety and efficacy. This treatment deeply impressed both patients and physicians; 75.4% and 78.3% respectively, over "the good". In addition, as the results of Wilcoxon's signed rank sum test for pain assessment (VAS, FS), both "Cumulative effect before and after treatment" and "Immediate effect before and after each administration" were confirmed to show a highly significant difference (p<0. 0001). Side effects were observed in five of 175 cases (2. 9%) but none of them were serious. Judging from the results of this study, TP therapy with NV was considered to be very useful for the treatment of myofascial pain in cancer patients.
authors: Development Department, Vitacain Pharmaceutical Co, Ltd.
authors: Asami
authors: A
authors: Yamaguchi
authors: Yoshio
authors: Y
authors: Ogino
authors: Chie
authors: C
authors: Iwakoshi
authors: Katsuhiro
authors: K
authors: Karasawa
authors: Masahiko
authors: M
authors: Ohki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009209:Myofascial Pain Syndromes / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000150:complications*
chemical_list: D000700:Analgesics